Joseph E.M. Crozier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Joseph E.M. Crozier has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Donald C. McMillan
Academic Unit of Surgery, School of Medicine, University of Glasgow, Glasgow Royal Infirmary, Glasgow G31 2ER, UK
2 shared publications C S McArdle
University Department of Surgery, Royal Infirmary Glasgow G31 2ER, UK
1 shared publicationE. Fiona Leitch
University Department of Surgery, Royal Infirmary, Glasgow G31 2ER, United Kingdom
1 shared publicationJ H Anderson
University Department of Surgery, Royal Infirmary Glasgow G31 2ER, UK
1 shared publicationJohn H. Anderson
University Department of Surgery, Royal Infirmary, Glasgow G31 2ER, United Kingdom
1 shared publicationP G Horgan
University Department of Surgery, Royal Infirmary Glasgow G31 2ER, UK
1 shared publication
Latest Publications
- Open Access
- 23 May 2006
- Published by Springer Nature in British Journal of Cancer
- Vol. 94 (12) , 1833-1836
The presence of a systemic inflammatory response predicts poorer survival in patients receiving adjuvant 5-FU chemotherapy following potentially curative resection for colorectal cancer
There is increasing evidence that the presence of a systemic inflammatory response plays an important role in survival following curative resection for colorectal cancer. The present study evaluated the relationship between C-reactive protein concentrations and survival in a cohort of patients receiving adjuvant 5-fluorouracil (5-FU) chemotherapy following potentially curative resection for colorectal cancer. In all, 222 patients undergoing potentially curative resection for colorectal cancer were studied. Of these, 50 patients received adjuvant 5-FU-based chemotherapy. Circulating concentrations of C-reactive protein were measured prior to surgery. The minimum follow-up was 15 months; the median follow-up of the survivors was 38 months. During this period 61 patients died, 32 patients of their cancer and 29 of intercurrent disease. In those patients who did not receive adjuvant chemotherapy, age (PPPP<0.01) was significantly associated with survival. The presence of a systemic inflammatory response is an independent predictor of poor outcome in patients receiving adjuvant 5-FU-based chemotherapy following potentially curative resection for colorectal cancer.
- 23 May 2006
- Published by Springer Nature in British Journal of Cancer
- Vol. 94 (12) , 1833-1836
Open AccessThe presence of a systemic inflammatory response predicts poorer survival in patients receiving adjuvant 5-FU chemotherapy following potentially curative resection for colorectal cancer
There is increasing evidence that the presence of a systemic inflammatory response plays an important role in survival following curative resection for colorectal cancer. The present study evaluated the relationship between C-reactive protein concentrations and survival in a cohort of patients receiving adjuvant 5-fluorouracil (5-FU) chemotherapy following potentially curative resection for colorectal cancer. In all, 222 patients undergoing potentially curative resection for colorectal cancer were studied. Of these, 50 patients received adjuvant 5-FU-based chemotherapy. Circulating concentrations of C-reactive protein were measured prior to surgery. The minimum follow-up was 15 months; the median follow-up of the survivors was 38 months. During this period 61 patients died, 32 patients of their cancer and 29 of intercurrent disease. In those patients who did not receive adjuvant chemotherapy, age (PPPP<0.01) was significantly associated with survival. The presence of a systemic inflammatory response is an independent predictor of poor outcome in patients receiving adjuvant 5-FU-based chemotherapy following potentially curative resection for colorectal cancer.
- 31 August 2005
- Published by Elsevier in The Surgeon
- Vol. 3 (4) , 277-279
Is the landmark technique safe for the insertion of subclavian venous lines?
- 31 August 2005
- Published by Elsevier in The Surgeon
- Vol. 3 (4) , 277-279
Is the landmark technique safe for the insertion of subclavian venous lines?